Community-based healthcare for Medicaid/low-income populations. NYC. General Catalyst + Alphabet. Raised $160M 2022. Addresses health equity.

Johnson & Johnson is a global healthcare company headquartered in New Brunswick, NJ, focused on preventing and curing complex diseases through smarter, less invasive treatments and personalized solutions. It was the first innovative healthcare company founded in New Jersey.

Brooklyn startup using AI to design and manufacture printed circuit boards (PCBs) in the US — attacking one of the most overlooked layers of the tech stack (PCBs power smartphones, satellites, medical devices, autonomous systems). Founded ~2024. Customers include Physical Intelligence and Saronic; partnered with Anthropic to help Claude become a better electrical engineer. Ambition: make hardware as nimble as software.

Cloud-based manufacturing-execution software platform for pharmaceutical and life-sciences manufacturers to manage drug production end-to-end.

Oncology data and analytics platform. NYC. First Round Capital + Google Ventures. Acquired by Roche $1.9B 2018.

North Jersey pharma giant (Rahway, NJ HQ) — the NYC-metro medicine chest.

Behavioral change platform for weight management and health. NYC. Sequoia + RRE Ventures. 45M+ users. Psychology-based mobile health.

East Hanover, NJ US base of the global pharma — North Jersey / NYC metro.

Technology-driven health insurance company. NYC. Thrive Capital + Alphabet/Google. IPO March 2021. $2B+ revenue. Co-founders: Mario Schlosser, Joshua Kushner, Kevin Nazemi.

Pfizer is one of the world's premier biopharmaceutical companies, headquartered in New York, NY. The company discovers, develops, and delivers medicines, vaccines, and consumer healthcare products globally, with more than 10,000 employees worldwide.

Direct-to-patient healthcare company. NYC. General Catalyst + SignalFire. Telehealth + pharmacy + lab. $7B valuation 2021.

Mental health benefits platform for employers. NYC. General Catalyst + Tiger Global. $3.3B valuation 2024. Raised $100M Series D 2024.